Ryan Savitz
EVP, CFO & CBO · 4 filings · Latest: Jul 9, 2026
Dianthus Therapeutics, Inc. /DE/
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
DNTH | Ryan Savitz | EVP, CFO & CBO | Jul 9, 2026 | Sale | $101.03 | 31,249 | $3.2M | 0 | |
DNTH | Ryan Savitz | EVP, CFO & CBO | Jul 9, 2026 | Option Exercise | $21.77 | 31,249 | $680.3K | 31,249 | |
DNTH | RYAN SAVITZ | — | Jul 9, 2026 | Proposed Sale | $98.07 | 31,249 | $3.1M | — | |
DNTH | Ryan Savitz | EVP, CFO & CBO | Apr 9, 2026 | Sale | $89.84 | 8,224 | $738.8K | 0 | |
DNTH | Ryan Savitz | EVP, CFO & CBO | Apr 9, 2026 | Option Exercise | $17.88 | 8,224 | $147.0K | 8,224 | |
DNTH | RYAN SAVITZ | — | Apr 9, 2026 | Proposed Sale | $87.48 | 8,224 | $719.4K | — | |
DNTH | Ryan Savitz | EVP, CFO & CBO | Mar 31, 2026 | Sale | $83.00 | 114,367 | $9.5M | 0 | |
DNTH | Ryan Savitz | EVP, CFO & CBO | Mar 31, 2026 | Option Exercise | $11.74 | 114,367 | $1.3M | 114,367 | |
DNTH | RYAN SAVITZ | — | Mar 31, 2026 | Proposed Sale | $79.45 | 114,367 | $9.1M | — | |
DNTH | RYAN SAVITZ | — | Dec 4, 2025 | Proposed Sale | $43.97 | 20,000 | $879.4K | — | |
DNTH | RYAN SAVITZ | — | Sep 9, 2025 | Proposed Sale | $31.80 | 20,000 | $636.0K | — |